Company Products. Section 2.7(c) of the Company Disclosure Letter sets forth a list of all material products, software or service offerings of the Company or any of its Subsidiaries that were sold within the past two (2) years or which the Company or any of its Subsidiaries intends to sell within ninety (90) days after the date hereof (collectively, “Company Products”).
Company Products. Schedule 2.10(d) of the Company Disclosure Letter lists all Company Products, and for each such product or feature (and each version thereof) identifying its release date.
Company Products. Section 3.18(d) of the Disclosure Schedule lists (i) all Company Products that the Company or any Subsidiary has made available for commercial use or purchase during the past five years, including any product or service currently under development and scheduled for commercial release within 90 days following the date of this Agreement, and for each such Company Product identifying planned approximate release date, and (ii) to the Company’s Knowledge, all Company Products that the Company or any Subsidiary made available for commercial use or purchase before the time period set forth in clause (i) above.
Company Products. (a) None of the products manufactured or sold by the Company or any of its Subsidiaries contains or incorporates asbestos, asbestos-containing materials, or presumed asbestos-containing materials.
(b) None of the products manufactured or sold by the Company or any of its Subsidiaries is subject to any guarantee, warranty, or other indemnity of or by the Company or any of its Subsidiaries beyond the applicable terms and conditions of sale and any additional written warranty provided by the Company and included with such product and any warranty imposed by law.
Company Products. “Company Products” means all products or service offerings of the Company or the Company Subsidiaries that have been marketed, sold, or distributed, or that the Company or any of the Company Subsidiaries intends to market, sell, or distribute in the conduct of the business of the Company or such Company Subsidiaries in the manner currently conducted and as it is currently contemplated to be conducted. Section 4.14(o) of the Disclosure Schedule sets forth a summary list of all Company Products.
Company Products. Section 2.14(b) of the Disclosure Schedule lists all Company Products and Future Products by name and version number.
Company Products. Section 2.13(a) of the Disclosure Schedule accurately identifies and describes each Company Product.
Company Products. Except as disclosed or contemplated in the SEC Reports, all products, systems, programs, services and Intellectual Property Rights that have been or are being developed, promoted, distributed, manufactured, rendered, sold and/or marketed by the Company or any of the Subsidiaries have been and are being developed, promoted, distributed, manufactured, rendered, sold and/or marketed in compliance and conformity in all material respects with all product specifications.
Company Products. (a) Since January 1, 1991, there have been no written notices, citations, or decisions by any governmental authority that any product produced, manufactured, or marketed at any time by the Company or its Subsidiaries (collectively, the "COMPANY PRODUCTS") is defective or fails to meet any applicable standards promulgated by such governmental authority. Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and its Subsidiaries are in compliance with the laws, regulations, policies, procedures, and specifications applicable to them with respect to the design, manufacture, labeling, testing, and inspection of the Company Products in the United States and the operation of manufacturing facilities in the United States promulgated by the Food and Drug Administration (the "FDA") or any other governmental authority that has jurisdiction over the design, manufacture, labeling, testing, and inspection of the Company Products and the operation of manufacturing facilities in the United States, and have complied with the laws, regulations, policies, procedures, and specifications applicable to the Company and its Subsidiaries in any jurisdiction outside the United States with respect to the design, manufacture, labeling, testing, and inspection of the Company Products and the operation of manufacturing facilities outside of the United States. Since January 1, 1991, there have been no recalls, field notifications, or seizures ordered or, to the knowledge of the Company, threatened by any governmental authority with respect to any of the Company Products, and the Company has not independently engaged in such recalls or field notifications. The Company has not received any warning letter or Section 305 notice from the FDA.
(b) The Company or one of its Subsidiaries has obtained, in all countries where the Company or any of its Subsidiaries is marketing or has marketed Company Products, all applicable permits, licenses, orders, authorizations, notifications and approvals required to be obtained by it by governmental authorities (including the FDA) in such countries regulating the safety, effectiveness, and market clearance of the Company Products that are currently marketed by the Company or its Subsidiaries, except where the failure to obtain such permits, licenses, orders, authorizations, notifications or approvals would not, individually or in the aggregate, reasonably be expected to have a C...
Company Products. Schedule 2.10(d) of the Company Disclosure Letter lists all Company Products. Except with respect to any Open Source Materials listed on Schedule 2.10(n) of the Company Disclosure Letter, Schedule 2.10(d) of the Company Disclosure Letter lists all Third-Party Intellectual Property incorporated into or distributed with each such Company Product, along with the applicable licensor of such Third-Party Intellectual Property and the applicable Company Intellectual Property Agreement under which the Company is licensed or otherwise authorized to use such Third-Party Intellectual Property.
